Y-mAbs Therapeutics price target lowered to $12 from $14 at BofA

BofA lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $12 from $14 and keeps a Neutral rating on the shares after the company issued guidance for 2025 and reiterated corporate priorities, including the establishment of Danyelza and radiopharmaceutical business units. The firm sees the realignment as a plus given the focus on Danyelza may help a waning launch, though it also notes guidance for this year “implies another year of rebuilding to growth.”